Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: Focus on ISIS 301012

Future Lipidology

Volumn 2, Issue 4, 2007, Pages 387-393

  Akdim, Fatima ^a   El Harchaoul, Karim ^a   Stroes, Erik S G ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antisense; Apolipoprotein B; Cholesterol; Low density lipoprotein; Oligonucleotide

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISIS 147764; ISIS 301012; ISIS 326358; LIPOSOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATTY LIVER; GENE SILENCING; GENE THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LIPOPROTEIN SYNTHESIS; LIVER TOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; RNA INTERFERENCE; SIDE EFFECT; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34547868506     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.4.387     Document Type: Article

References (37)

1. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97, 1440-1445 (1998).
2. Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
3. Grodos D, Tonglet R: Scandinavian simvastatin study (4S). Lancet 344(8939-8940), 1768 (1994).
4. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
5. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
6. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
7. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
8. Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection. evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
10. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459-467 (2000).
11. Ballantyne CM, Houri J, Notarbartolo A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107, 2409-2415 (2003).
12. Davidson MH, McGarry T, Bettis R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2125-2134 (2002).
13. Elovson J, Chatterton JE, Bell GT et al.: Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J. Lipid Res. 29, 1461-1473 (1988).
14. Crooke ST: Antisense drug technology. In: Principles, Strategies, and Applications. Crooke ST (Eds.) Marcel Dekker, Inc. NY, USA (2001).
15. Crooke ST: Progress in antisense technology. Annu. Rev. Med. 55, 61-95 (2004).
16. Bennett CF, Cowsert LM: Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim. Biophys. Acta 1489, 19-30 (1999).
17. Dashti N, Gandhi M, Liu X, Lin X, Segrest JP: The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry 41, 6978-6987 (2002).
18. Young SG: Recent progress in understanding apolipoprotein B. Circulation 82, 1574-1594 (1990).
19. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N. Engl. J. Med. 338, 1577-1584 (1998).
20. Veerkamp MJ, de GJ, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF: Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 22, 274-282 (2002).
21. Schonfeld G, Lin X, Yue P: Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol. Life Sci. 62, 1372-1378 (2005).
22. Di LE, Magnolo L, Lancellotti S et al.: Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia. J. Med. Genet. 44, 219-224 (2007).
23. Farese RV, Jr, Linton MF, Young SG: Apolipoprotein B gene mutations affecting cholesterol levels. J. Intern. Med. 231, 643-652 (1992).
24. Schonfeld G: The hypobetalipoprotainemias. Annu. Rev. Nutr. 15, 23-34 (1995).
25. Geary RS, Watanabe TA, Truong L et al.: Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligunucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897 (2001).
26. Graham MJ, Crooke ST, Monteith DK et al.: In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286, 447-458 (1998).
27. Yu RZ, Zhang H, Geary RS et al.: Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296, 388-395 (2001).
28. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
29. Kastelein JJ, Wedel MK, Baker BF et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
30. Chuang E, Lemonidas K, Whipple CP et al.: A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing human apoB-100 transgene. Atheroscler. Suppl. (2007) (Abstract).
31. Graham M, Tae-won K, Lemonidas K, Subramaniam A, Crooke R: Suppression of apoB by antisense oligonucleotides produces concomitant downstream reductions in lipogenic genes in mice and nonhuman primates. Circ. Res. 97(11) (2005) (Abstract 5010).
32. Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
33. Bradley J, Crooke R, Graham M, Wedel M: Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of ApoB in healthy volunteers. Circulation 112 (2005) (Abstract 727).
34. Geary R, Yu R, Bradley J, Chuang E, Wedel M, Vanvliet A: Lack of pharmacokinetic interactions of an antisense oligonucleotide targeting human apoB, when coadmistered with simvastatin and ezetemibe, in man. Atheroscler. Suppl. (2006) (Abstract).
35. Cuchel M, Bloedon LT, Szapary PO et al.: Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007).
36. Yue P, Tanoli T, Wilhelm O, Patterson B, Yablonskiy D, Schonfeld G: Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21. Metabolism 54, 682-688 (2005).
37. Crooke RM: Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin. Biol. Ther. 5, 907-917 (2005).